Medicinal products that are intended to improve digestion and metabolism, for example in Crohn’s disease, ulcerative colitis, short bowel syndrome or irritable bowel syndrome (IBS), are grouped by the G-BA into the category of diseases of the digestive system. Up until this time, xx products have been assessed in xx procedures. In the xx subpopulations assessed by the G-BA, xx% have displayed a major, XX% a considerable and XX% a minor additional benefit in relation to the comparative therapy. A non-quantifiable additional benefit has been proved for a weighted XX% of the subpopulations. At the same time, no additional benefit was seen in XX% of the subpopulations, corresponding to xx% of the xx million of the patients suitable for treatment with the assessed medicinal products.